John V. Oyler

New Capabilities

As of May 2026: Leading BeOne's China commercialization of tarlatamab

For decades, patients with extensive-stage small-cell lung cancer who relapsed after chemotherapy had almost nowhere to turn — five-year survival rates sat around 3%. Now a drug that bridges the patient's immune cells to their tumor has won approval in both the United States and China.

Updated May 31